SCHEMBL25745926

SCHEMBL25745926

CC(C)n1nc(C2CC2)cc(C(C)(C)C)c1=O

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ RET P07949 8/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ CYP3A4 P08684 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ MAP3K12 Q12852 1/20 0.31
▸ CYP1A2 P05177 1/20 0.30
▸ HCK P08631 1/20 0.30
▸ FGR P09769 1/20 0.30
▸ RPS6KB1 P23443 1/20 0.30
▸ FLT4 P35916 1/20 0.30
▸ KDR P35968 1/20 0.30
▸ MAP2K2 P36507 1/20 0.30
▸ MAP2K1 Q02750 1/20 0.30
▸ RPS6KA1 Q15418 1/20 0.30
▸ PLAT P00750 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25745860 0.80 KDM4E (0.38) KDM4EKMT2ARETSMN1; SMN2MAP3K12
SCHEMBL24816299 0.80 CACNA1H (0.34) KDM4ECYP3A4GAACYP2C19PLAT
SCHEMBL24007926 0.78 RET (0.40) KDM4EKMT2ARETSMN1; SMN2MAP3K12
SCHEMBL24816292 0.77 KDM4E (0.36) KDM4EKMT2ARETSMN1; SMN2CYP1A2
SCHEMBL25748100 0.76 KDM4E (0.36) KDM4EKMT2ARETSMN1; SMN2CYP1A2
SCHEMBL24007900 0.74 KDM4E (0.33) KDM4EKMT2ARETSMN1; SMN2
SCHEMBL24007919 0.74 TMIGD3 (0.43) KDM4EKMT2ARETSMN1; SMN2CYP3A4
SCHEMBL18055557 0.72 KDM4E (0.38) KDM4EKMT2ARETSMN1; SMN2MAP3K12
SCHEMBL6887721 0.72 MAP3K12 (0.40) KDM4EKMT2ARETMAP3K12
SCHEMBL25746177 0.71 RET (0.34) KDM4EKMT2ARETSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2023-08-24 — — US disclosed
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2023-08-24 — — US disclosed
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors AJAX THERAPEUTICS, INC. (US) 2023-07-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS JAK2, JAK3, STAT5B KDM4E 444/4885KMT2A 462/4885RET 113/4885
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors JAK2, JAK3, STAT5B KDM4E 444/4885KMT2A 462/4885RET 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback